

LIMITED  
SPECIAL OFFER  
Book before 20-July to save USD 400!

**THE ONLY CELL THERAPY FOCUSED  
TECHNICAL CONFERENCE IN ASIA!**



18 - 20 SEPTEMBER 2018 | SEOUL, SOUTH KOREA

-  **200+**  
Key Stakeholders from TOP Cell Therapy Companies
-  **50+**  
Asia-Pacific cell therapy companies to attend from Japan, China, Taiwan, Korea, Singapore, USA, Europe
-  **30+**  
Key opinion leaders to share their insights
-  **20+**  
Hours of Networking
-  **4**  
Roundtable discussions with CEOs of Asian Cell Therapy industry

**What is in it for you?**

- **Gain Latest Insights on:**
  - Regional cell therapy case studies on cancer and neurodegenerative diseases
  - Regulatory discussions for cell therapy products in Asia
  - Latest CAR-T cell therapy case studies
  - Cost effective manufacturing approaches
  - Latest developments in CAR-T cell therapy for solid tumor
- **Meet the leaders from Cesca Therapeutics, CARsgen Therapeutics, Kaedi Pharmaceuticals, Tella Pharma, Lion TCR, Eutilex, Medipost America, Taiwan Biotherapeutics, PT Kalbe Farma and many more in The Asian Cell Therapy Leaders Conclave on 18 September 2018**
- **Exclusive site tour to a cell therapy manufacturing facility in Seoul**










**ESTEEMED ADVISORY BOARD & PANEL OF SPEAKERS**

	<b>BG Rhee,</b> CEO, SCM Life Sciences, Korea		<b>Kampon Sriwatanakul,</b> CEO, Biosky Holding Inc., Thailand		<b>Ping Guo,</b> Vice President, Beijing YuanTang Institute of Gene Science, China
--	---	--	---	--	--

**INTERNATIONAL CELL THERAPY MANUFACTURERS**

	<b>Antonio Lee,</b> CEO, MEDIPOST America Inc., USA		<b>Dalip Sethi,</b> Senior Director of Process Development & Validation, Cesca Therapeutics, USA		<b>Deven Patel,</b> CEO, Giostar, USA
---	--	---	--	---	---

**ASIAN CELL THERAPY MANUFACTURERS**

	<b>Paul Dai,</b> CEO, Kaedi Pharmaceuticals, China		<b>Zonghai Li,</b> CEO, CARsgen Therapeutics, China		<b>Demao Yang,</b> Founder & CSO, Guangzhou Kang-Hong Therapeutics, China
	<b>Li Lie Tao,</b> CEO, Lion TCR, Singapore		<b>Yasumichi Hitoshi,</b> CEO, Thyas Co, Japan		<b>Hsiu ling Hsiao,</b> CSO, Ever Supreme Biotech, Taiwan
	<b>Sandy Qlintang,</b> Director of Stem Cell and Cancer Institute, PT Kalbe Farma, Indonesia		<b>Tong Young Lee,</b> CEO, Celtec, Taiwan		<b>Wei Chun Chen,</b> COO, Taiwan Biotherapeutics, Taiwan
	<b>Li Jianqiang,</b> CEO, Senlang Biotech, China		<b>Lin Yang,</b> CEO, PersonGen, China		<b>B. N. Manohar,</b> Managing Director, Stempeutics, India

**KOREAN CELL THERAPY MANUFACTURERS**

	<b>Jimmy Lee,</b> Director for R&D, S-Biomedics, Korea		<b>Kim Kyu-Tae,</b> Director, Abclon, Korea		<b>SunUk Song,</b> CSO, SCM Life Sciences, Korea
	<b>Myung Soo Cho,</b> Director of R&D, S-Biomedics, Korea		<b>Byoung S Kwon,</b> CEO, Eutilex, Korea		<b>Bae Shingyu,</b> CEO, Mdmune, Korea

# CELL THERAPY WORLD ASIA 2018

18th - 20th September 2018 | Seoul, South Korea

## 2018 SPONSORS

### ASSOCIATE SPONSOR

**TERUMOBCT**  
Unlocking the Potential of Blood



### EXHIBITORS

**eppendorf**

**Polyplus**  
transfection®

### WHY SHOULD YOU SPONSOR?

- Get cost-effective marketing exposure and branding to your target audience
- Position and profile yourself as an industry leader
- Enhance your brand recognition in the regional and global cell therapy industry
- Showcase new products and services to a targeted audience
- Develop partnerships through new networking opportunities

### WHO SHOULD SPONSOR?

#### WORLD-CLASS SOLUTION PROVIDERS WHO NEED TO POSITION THEIR PRODUCTS AND SERVICES IN FRONT OF DECISION MAKERS INCLUDE:

- Bioprocess/ Stem Cell Technology Service Providers
- Cell Separation/ Cell Sorters/ Cell Selector Vendors
- Cell Processing Vendors
- Cell Culture/ Media Vendors
- Bio-preservation Vendors
- Cell Characterization and Analytics
- Automated Temperature Monitoring Vendors
- Cellular Therapy Software Service Providers
- Cryogenic Storage System Providers
- Traceability Solutions
- Supply Chain and Logistics


**For sponsorship & exhibition opportunities, please contact:**

### CONTACT




**FARAH ARDLINA**  
farah.ardlina@imapac.com  
+65 3109 0125

### EXPECTED ATTENDEE PROFILE




#### GEOGRAPHY

- Europe
- Australia
- Korea
- Japan
- China
- Taiwan
- Others
- Rest of Asia



#### BY JOB TITLE

- CEO's, CSO's, CTO's, Presidents
- VP's, Directors, Heads of Cell Therapy and Regenerative Medicine
- Managers, Team Leaders, Research Scientists, Principal Scientists
- Professors, Heads of Depts
- Marketing & Business Development
- Others (Policy Makers & Government)



#### BY SECTOR

- Cell Therapy Companies & Biopharmas
- Big Pharma
- CMO's
- Academics
- Regulators & Government
- Vendors
- Others

### AGENDA AT A GLANCE

PRE-DAY	DAY 1	DAY 2
ASIAN CELL THERAPY LEADERS CONCLAVE & SITE TOUR	Asian Cell Therapy Landscape & Global Case Studies	Next Generation Car-T Cell Therapy Clinical Development and Manufacturing
	<b>SPEED NETWORKING BREAK</b>	
	Clinical Development Case Studies on Mesenchymal Stem Cell Therapy	Cancer Immunotherapy Case Studies And Reducing Cost of Goods
	<b>NETWORKING LUNCH</b>	
	Development & Commercialisation of Cell Therapy Case Studies	From Bench to Commercialisation : Case Studies of Cancer Cell Therapy in Asia
	<b>NETWORKING BREAK</b>	
	Novel Autologous Cell Therapies & Reducing Cost of Goods	Future of Cell Therapy Manufacturing in Asia
	<b>CONFERENCE ENDS</b>	<b>COCKTAIL RECEPTION</b>

**For speaking opportunities, please contact Aishwarya Pattanshetti**  
at [aishwarya.pattanshetti@imapac.com](mailto:aishwarya.pattanshetti@imapac.com) or call +65 3109 0124

# PRE-CONFERENCE DAY: ASIAN CELL THERAPY LEADERS CONCLAVE

## Attendees for CEO Conclave

Antonio Lee, CEO, MEDIPOST America Inc., USA	Bae Shingyu, CEO, Mdlmune, Korea	BG Rhee, CEO, SCM Life Sciences, Korea	B. N. Manohar, Managing Director, Stempeutics, India	Byoung S. Kwon, CEO, Eutilex, Korea	Dalip Sethi, Senior Director of Process Development & Validation, Cesca Therapeutics, USA	Demao Yang, Founder & CSO, Guangzhou Kang- Hong Therapeutics, China
Deven Patel, CEO, Giostar, USA	Hsiu ling Hsiao, CSO, Ever Supreme Biotech, Taiwan	Jaeseung Lim, CEO, Cellatoz Therapeutics, Korea	James Li, CEO, JW Therapeutics, China	Jeonghoon Han, Vice President, Eutilex Co. Ltd, Korea	Jianqiang Li, Founder & CSO, Hebei Senlang Biotechnology Group,China	Jimmy Lee, Director for R&D, S-Biomedics, Korea
Jong Sung Choi, Co-CEO, CHA Biotech, Korea	Junichi Miyazawa, CEO, Tella Pharma, Japan	Kampon Sriwatanakul, CEO, Biosky Holding Inc., Thailand	Kang Kyung San, Chairman, Kangstem, Korea	Kim Kyu-Tae, Director, Abclon, Korea	Lee Kyung-joon, CEO, JW CreaGene, Korea	Li Lie Tao, CEO, Lion TCR, Singapore
Lin Yang, CEO, PersonGen, China	Myung Soo Cho, Director of R&D, S-Biomedics, Korea	Paul Dai, CEO, Kaedi, China	Peggy Liu, VP, Lu Daopei Hospital, China	Sandy Qlintang, Director of Stem Cell and Cancer Institute, PT Kalbe Farma, Indonesia	SunUk Song, CSO, SCM Life Sciences, Korea	Tong Young Lee, CEO, Celtec, Taiwan
		Wei Chun Chen, COO, Taiwan Biotherapeutics, Taiwan	Yasumichi Hitoshi, CEO, Thyas, Japan	Zonghai Li, CEO, Carsgen, China		

13:30	<b>Registration &amp; Refreshments</b>
14:00	<b><u>ROUNDTABLE 1</u></b> Driving innovation for Commercialization of Cell Therapy Product in Asia
14:30	<b><u>ROUNDTABLE 2</u></b> Cost Reduction Strategies for Cell Therapy R&D and Manufacturing
15:00	<b>NETWORKING BREAK</b>
15:30	<b><u>ROUNDTABLE 3</u></b> Clinical Implementation and R&D expenditure management for new cell therapy products
16:00	<b><u>ROUNDTABLE 4</u></b> Evolving Regulations to Facilitate Access to Cell Therapies.
16:30	<b><u>Key takeaways from key round-table leaders</u></b>
17:00	<b>End of Conference</b>

*The Asian Cell Therapy Leaders Conclave 2018 is your best chance to interact with C-Level executives from Asia's leading cell therapy companies!*



## CONFERENCE PROGRAM

### DAY 1 - 19<sup>th</sup> SEP 2018

8:00 Registration

8:50 IMAPAC Producer's Opening Remarks

8:55 Chairman's Opening Remarks

## ASIAN CELL THERAPY LANDSCAPE & GLOBAL CASE STUDIES

9:00 **Reviewing the Stem Cell Therapy Industry and Its Emerging Markets**

- Discussion on current challenges and opportunities surrounding cutting edge research on stem cell therapy
- How to motivate government and capital markets to bring cell therapy to the commercialization stage

**Deven Patel, CEO, GIOSTAR, USA**

9:25 **TECHNOLOGY PRESENTATION:**

**Reserved for Solution Provider**

9:50 **KEYNOTE PRESENTATION:**

**Overview on global challenges and opportunities facing effective treatment for solid tumor**

- Discussion on Clinical Data for first CAR-T therapy for glioblastoma tumor in the world
- Discussion on challenges faced in management of cytokine release syndrome
- Next steps for CAR-T Cell Therapy for Solid Tumors

**Zonghai Li, CEO, CARsgen Therapeutics, China**

10:15

## SPEED NETWORKING BREAK

## CLINICAL DEVELOPMENT CASE STUDIES ON MESENCHYMAL STEM CELL THERAPY

11:00 **Clinical Development of Mesenchymal Stem Cell for the Treatment of Critical Limb Ischemia and Knee Osteoarthritis**

- Discussion on Phase I/II clinical trial results of Biochymal® & Chondrochymal®
- Therapeutic potential and challenges of using human Mesenchymal Stem Cells
- Strategies to improving the efficacy of human MSCs in the treatment of ischemic limb disease

**Wei Chun Chen, Chief Operating Officer, Taiwan Biotherapeutics, Taiwan**

11:25 **CASE STUDY :**

**Pneumostem® for The Prevention of Bronchopulmonary Dysplasia (Bpd) in Premature Infants**

- Discussion on late stage development of human Umbilical Cord Blood-derived MSC (hUCB-MSC) therapy on pediatric orphan indication.
- How to manage cross-country clinical development?
- Global regulatory and approval strategy for Orphan Regenerative Medicine products.

**Antonio Lee, CEO, Medipost America Inc, USA**

11:50 **CASE STUDY :**

**Clinical Development of Mesenchymal Stem Cell for Refractory Graft-Versus-host Disease**

- Discussion on Clinical Trial Results
- Strategies to evaluate safety and efficacy of MSCs
- How to overcome the limitations of this type of therapeutic approach

**Sun Uk Song, CSO, SCM Life Sciences, Korea**



12:15

## NETWORKING LUNCH

## DEVELOPMENT &amp; COMMERCIALISATION OF CELL THERAPY CASE STUDIES

13:45 **Overview of Stem Cell Therapy Manufacturing in Indonesia**

- Discussion on the current challenges and opportunities surrounding autologous stem cell therapy
- Future of cell therapy in 2025 and how to overcome the obstacles

**Sandy Qlintang**, *Director of Stem Cell Institute, PT Kalbe Farma, Indonesia*

14:10

**TECHNOLOGY PRESENTATION:**

Reserved for Terumo BCT

14:35 **Korean Cell Therapy Case-study: Overcoming the Challenges of Tumor Formation, Immunorejection & Differentiation for Parkinson's Disease**

- Discussion on Y-Stem-1 Clinical Trial Results
- How to overcome challenges in ESC Therapy such as tumor formation, immunorejection and differentiation
- Filing for Phase 1/2 IND approval; Do's and Don'ts

**Myung Soo Cho**, *Director of R&D, S-Biomedics, Korea*

15:00

## NETWORKING BREAK

## NOVEL AUTOLOGOUS CELL THERAPIES &amp; REDUCTING COST OF GOODS

15:45

**CASE STUDY :****Clinical Development of a Novel Immunotherapy for Chronic Diseases**

- Discussion on challenges and opportunities in clinical development
- Discussion on mechanism of action of immunotherapy
- How to prove safety and efficacy in small proof of concept clinical trials

**Demao Yang**, *Founder & CEO, Guangzhou Kang-Hon Therapeutics, China*

16:10

**Development of Innovative Therapeutics Based on CDV(Cell Derived Vesicle) for the Treatment of Cancer and COPD**

- Discussion on clinical trial results of autologous cell therapy for cancer
- Challenges in translating research to commercialization stage

**Bae Shingyu**, *CEO, Mdlmune, Korea*

16:35

**TECHNOLOGY PRESENTATION:**

Reserved for JW Creagene

17:00

Chairman Closing Remarks

17:10

Cocktail Reception



## CONFERENCE PROGRAM

DAY 2 - 20<sup>th</sup> SEP 2018

8:00 Registration

8:50 IMAPAC Producer's Opening Remarks

8:55 Chairman's Opening Remarks

## NEXT GENERATION CAR-T CELL THERAPY CLINICAL DEVELOPMENT AND MANUFACTURING

9:00 **Impact of Automated Single-Use Systems on Cost, Quality and Reproducibility of CAR-T Cell Therapy Manufacturing**

- Discussing the key drivers for shift to automated, closed single-use disposable systems?
- Meeting commercial demands of high dose cell therapies through Single Use technology
- Significant benefits of Automated systems such as cost reduction and lower risk of contamination

**Dalip Sethi, Senior Director of Process Development & Validation, Cesca Therapeutics, USA**9:25 **TECHNOLOGY PRESENTATION:****Reserved for Solution Provider**9:50 **CASE STUDY :****Using Methods Of HLA-DR (Human Leukocyte Antigen DR)CAR-T Therapy To Alleviate Side Effects Of CAR-T Cell Therapy**

- Discussion on new clinical study results and mechanism of action of human leukocyte antigen-DR (HLA-DR)-targeted CAR-T therapy
- Discussion on method of applying general T cell characteristics to alleviate the side effect
- Future goals and journey ahead

**Byoung S Kwon, CEO, Eutilex, Korea**10:15 **CASE STUDY :****Breakthrough Immunotherapy for Hepatocellular Carcinoma: Lion TCR**

- Discussion on clinical trial results of LTCR-H1-1
- Challenges and opportunities in developing unique TCR Cells for solid tumor
- Criteria for selecting target antigen for solid tumors
- How to manage cross border clinical trials effectively to ensure success?

**Li Lie Tao, CEO, Lion TCR, Singapore**

10:35

## SPEED NETWORKING BREAK

## CANCER IMMUNOTHERAPY CASE STUDIES AND REDUCING COST OF GOODS

11:20 **How to Develop Effective CAR-T cells and overcome Cell-mediated Tumor Toxicity**

- Overview of Taiwan's Cell Therapy Development
- How to manage toxic side effects of CAR-T cell therapy including cytokine release syndrome and neurologic side effects
- How can Asian Cell Therapy companies gain a competitive edge in the rat race for CAR-T Cell Therapy Approval?

**Hsiu Ling, CSO, Ever Supreme Biotech, Taiwan**

**11:45** **Case Study :****Clinical Development of Senl\_B19, a CD19 CAR-T Cell Therapy for treatment of B Linea Hematological Tumor**

- Discussion on preliminary results of phase ½ study
- Discussion on controlling side effects of Cytokine Release syndrome
- Steps ahead in advanced clinical testing

**Li Jianqiang, CEO, Senlang Biotech Co Ltd, China****12:10** **CASE STUDY :****High Efficacy & Safety of Low-Dose CD19 Directed CAR-T Cell Therapy for Refractory/Relapsed B Acute Lymphoblastic Leukemia**

- Discussion on data for treatment of 51 patients with CD19-directed CAR-T cell therapy
- Logistical challenges and limitations faced by clinicians for cell therapy
- How to improve partnership between cell therapy manufacturer and hospitals registering the cell therapy?

**Xian Zhang, Director of General Hematology and HLA Lab, Lu DaoPei Hospital, China****12:35****NETWORKING LUNCH****FROM BENCH TO COMMERCIALISATION : CASE STUDIES OF CANCER CELL THERAPY IN ASIA****14:00** **KEYNOTE PRESENTATION: CASE STUDY :****Clinical Development of Dendritic Cell Vaccine Vaccell® for Pancreatic Cancer**

- Discussion on promising clinical trial results in prolonging patients survival
- Challenges and opportunities for using dendritic cell vaccines for cancer in Asia
- Best approaches to differentiating, priming, and injecting dendritic cells to achieve maximal anti-tumor efficacy
- Technical and business considerations for commercialization of cell therapy product

**Junichi Miyazawa, CEO, Tella Pharma Inc, Japan****14:25** **Cracking CAR-T Solid Tumour Challenges : Challenges and Progress with New Approaches****Lin Yang, CEO, PersonGen, China****14:50** **JAPAN CASE STUDY :****Overcoming Limitations of Current Approaches in Autologous Cell Therapies Using Novel Anti-Tumor Cell Therapy and iPSC Technology**

- Introduction of a novel anti-tumor cell therapy with autologous/rejuvenated T cells utilizing iPSC technologies to overcome the limitations of current approaches
- Discussion on current challenges in development of Thyas T cell products
- Future developments and directions of autologous T cell immunotherapy utilizing iPSC technologies

**Yasumichi Hitoshi, CEO, Thyas Co., Japan****15:10****NETWORKING BREAK****FUTURE OF CELL THERAPY MANUFACTURING IN ASIA****15:00** **KEYNOTE PRESENTATION:****What does Next Generation T Cell Therapy Look Like**

- Overview on the recent developments and success with CAR-T therapies
- Challenges and Opportunities for CAR-T Cell therapy
- Key learning points for future fast-tracking of innovation

**Paul Dai, CEO, Kaedi Pharmaceuticals, China**



**16:25 CAR-T Case Study : Next Generation of Immune Cells in Taiwan**

- Overview of current status of CAR-T cell therapy in Taiwan
- Discussion on challenges surrounding cancer immunotherapy such as need for additional biomarkers, lack of clinical study designs for determining efficacy and high treatment costs
- Developmental goals for cell therapy in Taiwan by 2025 and how to get there

**Tong Young Lee, CEO, Celtec, Taiwan**

**16:50 Panel Discussion : Future of Cell Therapy Manufacturing in Asia**

- Discussion on the challenges and opportunities for Asia in the transition from R&D to commercialization including an evaluation of the manufacturing process, bio analytics and mitigation strategies.
- Collaboration strategies with global CMOs to maintain quality & uphold timelines
- Future Developments to improve transition from bench research to commercialization

**Kampon Sriwatanakul, CEO, Biosky Holdings, Thailand**

**Kim Kyu-Tae, Director, AbClon, Korea**

**Jimmy Lee, Director, S-Biomedics, Korea**

**17:20 Chairman Closing Remarks****17:30 End of Conference**